Study guide
4.3 Wilms Tumor and Other Renal Tumors
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
4.3 Wilms Tumor and Other Renal Tumors
Key Takeaways Explain This Topic AI
Wilms tumor peaks around 3–4 years as a painless abdominal mass; limit repeated palpation because of preoperative rupture and upstaging risk.
Predisposition syndromes WAGR, Beckwith-Wiedemann, and Denys-Drash drive serial abdominal ultrasound screening rather than waiting for a visible mass.
U.S. COG-style care typically uses upfront nephrectomy when feasible; SIOP protocols use neoadjuvant chemotherapy before surgery.
Favorable versus anaplastic histology and stages I–V (V is bilateral), plus lung metastases, drive vincristine, dactinomycin, doxorubicin, and radiation for higher-stage or ruptured disease.
Clear cell sarcoma seeds bone, rhabdoid tumor is a young-child aggressive disease that warrants brain imaging, and congenital mesoblastic nephroma is an infant tumor often cured with surgery. Hypertension, residual renal function, and anthracycline cardiac surveillance are long-term nursing priorities.
Last updated: August 2026
Wilms tumor (nephroblastoma) is the most common primary renal malignancy of childhood. Peak age is about 3 to 4 years . The classic presentation is a painless abdominal mass noticed in the bath or by a relative who has not seen the child for a month. Hematuria, fever, and hypertension from renin-mediated compression of the renal vasculature are common companions. CPHON items punish two errors: treating the belly like a physical-diagnosis toy, and treating every pediatric renal mass as if it were favorable-histology Wilms.
Do not palpate the tumor into a higher stage
Repeated deep palpation risks preoperative rupture and peritoneal spillage, which upstages disease and can add radiation. One careful exam to confirm a mass is enough. After that, imaging—not shift-by-shift bimanual exams—tracks size. Teach students and families: hands off the flank. Preoperative rupture can also occur spontaneously or at surgery; document any abdominal trauma and handle transfers with the same caution you would use for a full bladder of chemotherapy.
A 3-year-old with a firm, nontender, unilateral flank mass, mild hypertension, and microscopic hematuria is Wilms until imaging and histology say otherwise. Do not order a trial of massage to shrink the mass, and do not let every learner on the team recheck the size.
Syndromes that change screening, not just trivia
Three predisposition syndromes belong in active nursing memory because they change screening :
WAGR syndrome : Wilms tumor, Aniridia , Genitourinary anomalies, and Range of developmental delay —a contiguous-gene deletion involving WT1 and PAX6. Absent iris is the physical clue in clinic.
Beckwith-Wiedemann syndrome : overgrowth, macroglossia, omphalocele or umbilical hernia, hemihypertrophy, and elevated risk of Wilms tumor and hepatoblastoma. Serial abdominal ultrasound (and often serum alpha-fetoprotein for hepatoblastoma in early years) is the screening principle—do not wait for a visible mass.
Denys-Drash syndrome : WT1-related nephropathy (diffuse mesangial sclerosis and early renal failure), 46,XY gonadal dysgenesis or ambiguous genitalia, and a high Wilms risk.
Screening principle: children with these diagnoses, and isolated hemihypertrophy in many programs, receive periodic abdominal ultrasound on a schedule set by the genetics and oncology teams, commonly every 3 months in early childhood. Teach families that a normal last scan does not make the next one optional. After a Wilms diagnosis, still look backward for aniridia, hemihypertrophy, and nephropathy—the contralateral kidney may be at risk.
Syndrome Clinical clues Screening implication
WAGR Aniridia, genitourinary anomalies, developmental delay Serial abdominal ultrasound; genitourinary and developmental care
Beckwith-Wiedemann Macroglossia, omphalocele, hemihypertrophy Serial abdominal ultrasound; alpha-fetoprotein as the program specifies
- Denys-Drash Early nephropathy, ambiguous genitalia High Wilms risk; renal-failure planning
- Isolated hemihypertrophy Asymmetric growth Many programs still ultrasound-screen in early childhood
- Histology, stage, and two philosophies of timing
Favorable histology (triphasic blastema, epithelium, and stroma, without anaplasia) is the common, more chemosensitive group. Anaplastic (unfavorable) histology changes intensity and radiation decisions. Staging in Children’s Oncology Group (COG) practice is surgical-pathologic:
Stage I : tumor confined to the kidney, completely resected.
Stage II : extends beyond the kidney but completely resected.
Stage III : residual tumor, positive lymph nodes, rupture or spillage, or incomplete resection.
Stage IV : hematogenous metastases; lung is the most common site.
Stage V : bilateral renal involvement at diagnosis.
COG versus SIOP is a philosophy question, not a morality question. COG-style care in the United States typically performs upfront nephrectomy when feasible , then assigns adjuvant therapy from true pathologic stage and histology. International Society of Paediatric Oncology (SIOP) protocols, widely used in Europe, give neoadjuvant chemotherapy first, then surgery, which can shrink tumors and reduce rupture risk but means preoperative stage is imaging-based. Neither approach is wrong; CPHON expects you to know that U.S. practice is usually COG/upfront surgery when the tumor is resectable , and that inoperable, extensive, or bilateral disease may still receive preoperative chemotherapy even in COG settings. Do not tell a family that SIOP is illegal in North America or that every U.S. child must get 6 weeks of chemotherapy before the operating room.
Bilateral (stage V) disease is a kidney-sparing problem: the goal is tumor control and residual nephrons. Nephron-sparing surgery after chemotherapy is common. Lung nodules, when they represent metastases, add pulmonary-directed therapy—chemotherapy intensity and, in selected cases, lung radiation—per protocol.
Drugs, radiation, and other renal tumors that are not Wilms
Backbone agents are vincristine and dactinomycin . Doxorubicin is added for higher-stage or unfavorable disease. Radiation is used for higher stage, rupture or spillage, residual disease, and selected metastatic sites—not for every completely resected stage I favorable tumor. Vincristine brings constipation and neuropathy; dactinomycin can cause hepatopathy (a veno-occlusive-like illness), especially when combined with radiation; doxorubicin requires long-term cardiac surveillance with echocardiography because anthracycline cardiomyopathy can appear years later.
Not every pediatric renal mass is Wilms:
Clear cell sarcoma of the kidney has a reputation for bone metastases ; bone scan belongs in the workup. It is treated more intensively than favorable Wilms.
Rhabdoid tumor of the kidney strikes very young infants and toddlers, is highly aggressive, and is associated with CNS rhabdoid tumors (atypical teratoid/rhabdoid tumor biology). Brain MRI is part of staging.
Congenital mesoblastic nephroma is a tumor of infants , often in the first months of life, and is frequently cured with surgery alone.
A 3-week-old with a renal mass is mesoblastic nephroma until proven otherwise; a 10-month-old with a viciously aggressive renal tumor and a brain lesion is rhabdoid until proven otherwise; a 3-year-old with a painless flank mass is Wilms until proven otherwise.
Hypertension, the remaining kidney, and survivorship
Treat hypertension; do not ignore it as pain. After unilateral nephrectomy, residual renal function is a lifelong nursing topic: avoid nephrotoxic habits, treat urinary infections, watch blood pressure, and caution with contact sports and nonsteroidal anti-inflammatory overuse as the child grows. Families need a sick-day plan that does not assume two spare kidneys. If doxorubicin was given, schedule echocardiographic follow-up even when the child looks fine. Pulmonary radiation, when used, adds lung and breast-field late-effect counseling in girls.
The CPHON picture is a preschooler with a bath-time mass, a please-do-not-poke-this-belly sign on the door, a WAGR or Beckwith screening ultrasound that found a lesion before it was visible, a COG-style trip to the operating room, vincristine–dactinomycin with or without doxorubicin, and a survivorship folder that includes the remaining kidney and the heart.